This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME activities may not contain the most up-to-date information available. Click here to view our current activities in Oncology. Click to download the newsletters or to order printed versions Dear Colleague: Despite the fact that more men than ever are undergoing screening for prostate cancer, this disease remains the most common nonskin cancer among men, and the second leading cause of cancer-related death after lung cancer. Hormone therapy can offer partial tumor control or even regression, but all prostate cancers eventually become refractory to hormone therapy. New chemotherapy options with combinations of microtubule inhibitors now offer longer survival—up to 20 months—for patients with these hormone-refractory prostate cancers. These agents, which include estramustine, the taxanes (docetaxel and paclitaxel), and the vinca alkaloids (vinblastine, vincristine, and vinorelbine), trigger molecular mechanisms that deactivate the oncogene-derived protein, BCL-2, and, in turn, initiate programmed cell death (apoptosis). A challenging issue in the management of prostate cancer is the optimal time to begin chemotherapy. Whereas some clinicians advocate for a “watchful waiting” approach, others opt for initiating chemotherapy immediately after diagnosis. Another issue of debate is the appropriate time to refer a patient with prostate cancer for treatment. Two case studies are presented in this newsletter, which address the optimal time to initiate treatment and offer practical strategies for individualizing patient care. We are pleased to offer you New Prospects in the Treatment of Hormone-Refractory Prostate Cancer, a CME newsletter that offers medical oncologists the latest information on microtubule inhibitor therapy and presents insights into future biologic treatments. We hope that you find this newsletter helpful and informative. Sincerely, Co-Chair Alan J. Koletsky, MD, FACP National Program Director   Urologic Oncology Palm Beach Regional   Medical Director Boca Raton Comprehensive   Cancer Center, A Salick   Health Care Affiliate Boca Raton, Florida   Co-Chair Daniel P. Petrylak, MD Associate Professor of Medicine Presbyterian Hospital Director, Genitourinary   Oncology Program New York, New York Download & Order Form Click the images above to download the TxReporter Newsletters in Adobe Acrobat® PDF format (get the free Reader) OR Fill out the form below to have the paper versions sent to you. Fill out the fields below. *Required *First name MI *Last name *Credentials (eg, MD, DO, etc) *Office address Line1 Office address Line2 *City *State *ZIP *Office Phone for confirmation only *Office Fax for confirmation only *E-mail Specialty top Recommend this to a colleague World Wide Web pages are copyrighted and may not be reproduced in any form without the express written consent of Projects In Knowledge, Inc.SM Copyright © 2004, Projects In Knowledge, Inc. All rights reserved. For questions or comments regarding this web site please contact: Webmaster